Eagle Pharmaceuticals Announced That The First Patient Has Been Randomized In Its Phase 2 Study Of CAL02 For Severe Community-acquired Bacterial Pneumonia; The Plans To Enroll Approximately 276 Patients; First 50% Interim Report Is Expected Around Q1 2024
Portfolio Pulse from Benzinga Newsdesk
Eagle Pharmaceuticals has announced the initiation of its Phase 2 study of CAL02 for severe community-acquired bacterial pneumonia, with the first patient being randomized. The study plans to enroll approximately 276 patients, with the first interim report expected around Q1 2024.
July 24, 2023 | 10:52 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Eagle Pharmaceuticals' initiation of Phase 2 study for CAL02 could potentially boost its stock as it indicates progress in the company's pipeline. However, results are not expected until Q1 2024, which may limit immediate impact.
The initiation of a Phase 2 study is a significant milestone for any pharmaceutical company, indicating progress in the development of its drug pipeline. This could potentially boost investor confidence in Eagle Pharmaceuticals, leading to a positive impact on its stock. However, as the first interim report is not expected until Q1 2024, the immediate impact on the stock may be limited.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 100